Loading…
No business profile yet.
Size Electra Therapeutics (ETRA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $530M, the 2634th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.43 on 18 Nov 2026.
Short interest Short interest is 0.8% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$61,000 | $0 |
| EBITDA | n/a | -$61.8M | -$26.3M |
| Net income | n/a | -$62.0M | -$24.8M |
| Free cash flow | n/a | -$61.2M | -$26.0M |
| Capital expenditure | n/a | $733,000 | $0 |
| Total debt | $1.71M | $2.09M | $0 |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ETRA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.3% | -7.2% | 7th highest of 20 |
| Distance from 52-week high | -45.6% | -38.7% | 4th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | 0.7× | 2.4% | +5.0% |
| Supriya Lifescience SUPRIYA.NS | India | $529M | -15% | +23% | 26% | 5.5× | 28.2% | +15.8% |
| Evonile Pharma EVONILE.NS | India | $529M | n/a | -5% | 12% | 16.2× | 49.3% | -1.5% |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | 6.6× | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 7.4× | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | 2.2× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $517M | -29% | -11% | -8% | 5.6× | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | 2.3× | -6.1% | +9.6% |
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 1.8× | 1.0% | +9.7% |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 71.0× | n/a | n/a |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 1.0× | -12.3% | +11.1% |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 2.4× | -4.9% | +51.6% |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 0.9× | -3.1% | +12.6% |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | 69.1× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | 27.2× | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 1.2× | -5.8% | +4.1% |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | 4.8× | -5.4% | +7.6% |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | 4.0× | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | 6.2× | n/a | n/a |